Built for small pharma

Enterprise-grade development work, without the enterprise.

Graticus gives small and emerging pharma teams three things large companies take for granted: a tool that turns a molecule into a fully cited development brief in under three minutes, thirteen four-hour simulations that let your team make the expensive decisions before they cost anything, and senior counsel when the call is hard.

See a sample briefStart a conversation
Protocol Generator Training AdvisoryEst. 2026 · Small Pharma
01 / Services

Three offerings. One firm. Priced so a company of eleven can actually buy them.

01 · Protocol Generator

From a structure to a development brief in under three minutes.

Give it a compound name, upload a structure image, or draw it. Nothing generates until you confirm the structure is the one you meant. Then the Protocol Generator pulls the evidence — PubChem, ChEMBL, Europe PMC, ClinicalTrials.gov, EPO patent records — builds a citation register, and writes a nine-section development brief you can put in front of a partner.

See a sample briefRequest access

What you get

  • A versioned Word document with a full citation register attached
  • Executive summary, compound profile, target product profile, comparable compounds, development considerations, IP and risk landscape, open questions
  • Every claim traced to a registered source. A section citing something ungrounded is regenerated once, then failed rather than shipped.
  • A development plan that is not written by a model — it comes from a regulatory rules engine and a critical-path scheduler, so nothing in the schedule can be invented
  • The plan converts into a real project: a typical small-molecule program to IND/CTA-ready lands at roughly 30 milestones and 230 tasks across 252 days, with the critical path marked

On your molecule

  • It never touches our pharma business. It does go to public chemistry, literature and patent databases, and to the model that writes the prose. Every customer runs on their own deployment, and we put the data handling in writing before you upload anything.
  • A support tool, not the last word. The brief gets a competent team to the starting line faster with every claim traceable and every gap named. Your scientist, your regulatory lead and your patent attorney still decide.

Pricing

Single brief — $3,500
One compound, the complete document and register. Credited in full against a subscription if you continue.
Program access — from $1,750/month
Billed annually. Dedicated instance, up to 24 briefs a year, project-plan conversion included.
Full dashboard — from $3,500/month
Adds regulatory tracking, IP, vendor management and data room.
02 · Training

Make the expensive decisions in a simulation first.

Thirteen decision simulations that put your team in the chair with a runway, a molecule and a call to make. Each one teaches before the decision and explains the reasoning after it, so people leave knowing why the strong answer was strong — not just which button was right.

Try a simulationSign in

What a simulation actually is

  • Four hours. Ten modules. Up to forty decisions. Not a quiz and not a webinar — long-form work, designed to be done across several sittings.
  • Teaching comes before each decision. The reasoning comes after it.
  • Progress saves. People pick up where they left off.

Two tracks

  • Founder track — regulatory strategy, licensing, capital, exit
  • Technology transfer track — written from the TTO side of the table
  • Or the full catalogue: thirteen simulations, roughly fifty hours of decision practice
  • Simulations can be tailored to your own programme

Pricing

Single simulation — $450 per seat
Try one before you commit a team.
Single track — $1,800 per seat per year
About twenty-four hours of content. Minimum 5 seats.
Full catalogue — $2,750 per seat per year
All thirteen. Minimum 5 seats.
Facilitated workshop — $7,500
One simulation, run as a session for up to fifteen people.

For context: a three-day industry conference costs about the same per person and produces twenty hours of sitting in rooms.

03 · Advisory

Senior help at the point where most advisors go quiet.

Licensing strategy, partner identification, deal structuring, regulatory and commercial pathway planning, and interim leadership — from people who have built and transacted in pharma, not just advised on it.

Enquire

What you get

  • Licensing and out-licensing strategy
  • Partner identification and deal structuring
  • Regulatory and commercial pathway planning
  • Interim leadership and fractional CBDO support

How it works

  • We answer every enquiry within two business days
  • We take on few engagements at a time so the ones we take on get the room

Pricing

Strategy sprint — $12,500
Three weeks, fixed fee, fixed scope. A licensing readiness assessment, a partner landscape, or a pathway review, delivered as a document you can act on.
Retained advisory — from $7,500/month
Three-month minimum. Ongoing counsel through a live process.
02 / Approach

The name we chose is the standard we hold.

01

Graticule — we measure before we advise.

A graticule is the crosshair inside a microscope. It is the quiet instrument by which something small becomes legible. We begin every engagement the same way: by looking carefully at where you actually are, not where you want to be.

02

Small pharma deserves enterprise-grade support.

The tools and counsel that move molecules to market have historically been available only to large organizations, at five and six figures a year. We built Graticus to close that gap — because the best science is not always inside the largest companies.

03

Invictus — we hold the line when the work gets difficult.

Programs stall. Funding tightens. Partners go quiet. Our value is highest at the exact moment most advisors become scarce. We stay in the room and do the work until the outcome is resolved.

04

Tools and strategy are not separable.

The tools are not products we license and leave. What your team builds inside them informs every strategic conversation we have. Equally, each stands on its own — most customers take one and never need the rest.

03 / Industries

Where we do our best work.

01
Pre-clinical and early-stage companies

Taking a molecule toward a first partner conversation.

02
Drug delivery and reformulation platforms

Including 505(b)(2) programs, where the science is strong and the development path is the hard part.

03
Technology transfer offices and university spin-outs

Deciding which assets to move and how to structure the deal.

We also work with specialty pharma, clinical-stage biotech, nutraceutical and OTC developers, and emerging-market pharma companies.

Who we are not for: large organizations that already have this infrastructure in place, and teams looking for someone to do the science for them. We sharpen the work; we do not replace the scientist.

Precision is a kind of respect. It is the only way to honor the science — and the patients waiting at the end of it.
Graticus · Founding Principle

Start a conversation.

Tell us about your pipeline, your team, and the decision in front of you. We respond within two business days — usually faster.

hello@graticus.com